Targeted Therapy & Precision Oncology
Part of Healthcare - Oncology
 LLY | Eli Lilly & Co. | $1.0t | $1138.88 | +0.2% | 1.2K |
 RVMD | Revolution Medicines, Inc. Common Stock | $45.2b | $204.94 | 0.0% | 47 |
 INCY | Incyte Genomics Inc | $26.1b | $123.08 | 0.0% | 32 |
 JAZZ | Jazz Pharmaceuticals, Inc. | $15.9b | $242.92 | 0.0% | 930 |
 EXEL | Exelixis Inc | $14.5b | $57.00 | 0.0% | 4.6K |
 HALO | Halozyme Therapeutics, Inc. | $12.4b | $108.90 | 0.0% | 212 |
 CORT | Corcept Therapeutics Inc. | $11.9b | $109.95 | 0.0% | 2 |
 NUVL | Nuvalent, Inc. Class A Common Stock | $9.8b | $123.96 | 0.0% | N/A |
 COGT | Cogent Biosciences, Inc. Common Stock | $6.0b | $33.08 | 0.0% | 60 |
 ERAS | Erasca, Inc. Common Stock | $5.7b | $15.96 | 0.0% | 318 |
 CELC | Celcuity Inc. Common Stock | $4.7b | $82.75 | 0.0% | 24 |
 ELVN | Enliven Therapeutics, Inc. Common Stock | $4.2b | $53.37 | 0.0% | N/A |
 RLAY | Relay Therapeutics, Inc. Common Stock | $4.2b | $18.84 | 0.0% | 50 |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | $3.9b | $37.66 | 0.0% | N/A |
 TNGX | Tango Therapeutics, Inc. | $3.8b | $23.89 | 0.0% | N/A |
 IMNM | Immunome, Inc. | $3.1b | $24.12 | 0.0% | N/A |
 NRIX | Nurix Therapeutics, Inc. Common stock | $2.6b | $24.88 | 0.0% | 4.2K |
 NUVB | Nuvation Bio Inc. | $2.4b | $5.77 | -0.3% | 969 |
 BHVN | Biohaven Ltd. | $2.4b | $12.49 | 0.0% | 4 |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.52 | -0.0% | 3.0M |
 URGN | UroGen Pharma Ltd. Ordinary Shares | $2.2b | $41.81 | 0.0% | N/A |
 ZYME | Zymeworks Inc. | $2.1b | $26.10 | 0.0% | 93 |
 NVCR | NovoCure Limited Ordinary Shares | $2.1b | $15.76 | 0.0% | 3 |
 VIR | Vir Biotechnology, Inc. Common Stock | $1.9b | $10.45 | 0.0% | 5 |
 DMRA | Damora Therapeutics, Inc. Ordinary Shares | $1.7b | $25.25 | 0.0% | 248 |
 AVBP | ArriVent BioPharma, Inc. Common Stock | $1.5b | $27.98 | 0.0% | 570 |
 TYRA | Tyra Biosciences, Inc. Common Stock | $1.5b | $25.49 | 0.0% | 3.9K |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | $1.3b | $12.38 | 0.0% | 50 |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $1.2b | $13.00 | 0.0% | 51 |
 KURA | Kura Oncology, Inc. | $1.2b | $11.35 | 0.0% | 53 |
 GERN | Geron Corp | $1.0b | $1.30 | 0.0% | 16 |
 OLMA | Olema Pharmaceuticals, Inc. Common Stock | $0.9b | $9.90 | 0.0% | N/A |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.9b | $44.36 | 0.0% | N/A |
 MNPR | Monopar Therapeutics Inc. Common Stock | $0.8b | $103.53 | 0.0% | N/A |
 NVCT | Nuvectis Pharma, Inc. Common Stock | $0.8b | $21.93 | 0.0% | N/A |
 VSTM | Verastem, Inc. | $0.7b | $7.45 | 0.0% | N/A |
 BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $0.7b | $4.88 | 0.0% | N/A |
 ARVN | Arvinas, Inc | $0.6b | $8.26 | 0.0% | 4 |
 DCTH | Delcath Systems Inc | $0.6b | $16.18 | 0.0% | N/A |
 PBYI | PUMA BIOTECHNOLOGY INC | $485.7m | $9.26 | 0.0% | N/A |
 CCCC | C4 Therapeutics, Inc. | $466.3m | $3.44 | 0.0% | N/A |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $466.1m | $4.55 | 0.0% | N/A |
 PRLD | Prelude Therapeutics Incorporated | $419.0m | $4.54 | 0.0% | N/A |
 ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | $389.1m | $3.20 | 0.0% | N/A |
 STRO | Sutro Biopharma, Inc. | $340.6m | $16.55 | 0.0% | N/A |
 IMRX | Immuneering Corporation Class A Common Stock | $324.8m | $4.69 | 0.0% | 585 |
 TLSI | TriSalus Life Sciences, Inc. Common Stock | $306.6m | $4.79 | 0.0% | N/A |
 PYXS | Pyxis Oncology, Inc. Common Stock | $297.3m | $3.22 | 0.0% | 2 |
 WHWK | Whitehawk Therapeutics, Inc. Common Stock | $264.0m | $4.08 | 0.0% | N/A |
 CRBP | Corbus Pharmaceuticals Holdings, Inc. | $222.0m | $6.82 | 0.0% | 3.7K |